JP2024519545A5 - - Google Patents

Info

Publication number
JP2024519545A5
JP2024519545A5 JP2023573168A JP2023573168A JP2024519545A5 JP 2024519545 A5 JP2024519545 A5 JP 2024519545A5 JP 2023573168 A JP2023573168 A JP 2023573168A JP 2023573168 A JP2023573168 A JP 2023573168A JP 2024519545 A5 JP2024519545 A5 JP 2024519545A5
Authority
JP
Japan
Prior art keywords
bcma
specific antibody
composition according
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519545A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/064362 external-priority patent/WO2022248642A1/en
Publication of JP2024519545A publication Critical patent/JP2024519545A/ja
Publication of JP2024519545A5 publication Critical patent/JP2024519545A5/ja
Pending legal-status Critical Current

Links

JP2023573168A 2021-05-28 2022-05-26 B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma Pending JP2024519545A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163194470P 2021-05-28 2021-05-28
US63/194,470 2021-05-28
US202163209694P 2021-06-11 2021-06-11
US63/209,694 2021-06-11
PCT/EP2022/064362 WO2022248642A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Publications (2)

Publication Number Publication Date
JP2024519545A JP2024519545A (ja) 2024-05-15
JP2024519545A5 true JP2024519545A5 (cg-RX-API-DMAC7.html) 2025-05-26

Family

ID=82115891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573168A Pending JP2024519545A (ja) 2021-05-28 2022-05-26 B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma

Country Status (10)

Country Link
US (1) US20220411525A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519545A (cg-RX-API-DMAC7.html)
KR (1) KR20240014482A (cg-RX-API-DMAC7.html)
CN (1) CN119679935A (cg-RX-API-DMAC7.html)
AU (1) AU2022281104A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024822A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221399A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014139A (cg-RX-API-DMAC7.html)
WO (1) WO2022248642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Similar Documents

Publication Publication Date Title
Peters et al. Pathophysiology and treatment of psoriasis
JP2022180461A5 (cg-RX-API-DMAC7.html)
JP2024523003A5 (cg-RX-API-DMAC7.html)
JP2004512262A5 (cg-RX-API-DMAC7.html)
AR040603A1 (es) El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
Katsambas et al. A double‐blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream
JP2023517243A5 (cg-RX-API-DMAC7.html)
JP2019526595A5 (cg-RX-API-DMAC7.html)
JP2022188083A5 (cg-RX-API-DMAC7.html)
JP2017537927A5 (cg-RX-API-DMAC7.html)
DE112011102638T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Behandlung und Prävention der Krankheiten, die durch HIV verursacht werden oder mit HIV zusammenhängen
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
JP2020512361A5 (cg-RX-API-DMAC7.html)
JP2020523384A5 (cg-RX-API-DMAC7.html)
JP2022523530A5 (cg-RX-API-DMAC7.html)
JP2022028788A5 (cg-RX-API-DMAC7.html)
JP2021075563A (ja) 15−オキソ−epaまたは15−オキソ−dglaを含む組成物、ならびにその作製及び使用方法
RU2007134368A (ru) Способы лечения лимфом с использованием сочетания химиотерапевтического средства и il-2, и, не обязательно, антител анти-cd20
JP2021522246A5 (cg-RX-API-DMAC7.html)
KR20180017145A (ko) 소양증의 치료
RU2020120876A (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
DE112008000888T5 (de) Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen
JP2018529747A5 (cg-RX-API-DMAC7.html)
JP2024535880A5 (cg-RX-API-DMAC7.html)